Synthesis of jaspaquinol and effect on viability of normal and malignant bladder epithelial cell lines

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 11, 2004, Pages 2883-2887

  Demotie, Alexandre ^a   Fairlamb, Ian J S ^a   Lu, Feng Ju ^a   Shaw, Nicola J ^a   Spencer, Peter A ^a   Southgate, Jennifer ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATIC COMPOUND; JASPAQUINOL; TERPENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CARCINOMA; BLADDER EPITHELIUM; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; HUMAN CELL; REACTION ANALYSIS; STILLE REACTION;

BENZENE; CELL LINE, TUMOR; CELL SURVIVAL; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 2342534553     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.055     Document Type: Article

References (27)

1. Murray L.M., Johnson A., Diaz M.C., Crews P. J. Org. Chem. 62:1997;5638
2. Carroll J., Jonsson E.N., Ebel R., Hartman M.S., Holman T.R., Crews P. J. Org. Chem. 66:2001;6847
3. Biller S.A., Neuenschwander K., Ponpipom M.M., Poulter C.D. Curr. Pharm. Des. 2:1996;1
4. Leonard D.M. J. Med. Chem. 40:1997;2971
5. Lebowitz P.F., Prendergast G.C. Oncogene. 17:1998;1439
6. Marriott J.H., Moreno Barber A.M., Hardcastle I.R., Rowlands M.G., Grimshaw R.M., Neidle S., Jarman M. J. Chem. Soc., Perkin Trans. 1. 2000;4265
7. Fairlamb I.J.S., Pike A.C., Ribrioux S.P.C.P. Tetrahedron Lett. 43:2002;5327
8. Fairlamb I.J.S., Dickinson J.M., Pegg M., Cohen L.H., van Thiel C. Bioorg. Chem. 31:2003;80
9. Mechelke M., Wiemer D.F. J. Org. Chem. 64:1999;4821
10. Mechelke M., Wiemer D.F. Tetrahedron Lett. 39:1998;783
11. For recent references see: Radetich B., Corey E.J. J. Am. Chem. Soc. 124:2002;2430
12. Liu X.-H., Prestwich G.D. J. Am. Chem. Soc. 124:2002;20
13. Sharpless K.B., Umbreit M.A. J. Am. Chem. Soc. 99:1977;5526. and references cited therein
14. 2, see: Fairlamb I.J.S., Dickinson J.M., Pegg M. Tetrahedron Lett. 42:2001;2205
15. Available in three steps from β-ionone, see: Crombie B.S., Smith C., Varnavas C.Z., Wallace T.W. J. Chem. Soc. Perkin Trans. 1. 2001;206. and references cited therein
16. Corey E.J., Kim C.U., Takeda M. Tetrahedron Lett. 13:1972;4339
17. Barrero A.F., Alvarez-Manzaneda E.J., Chahboun R., Díaz C.G. Synlett. 2000;1561
18. Various Pd-complexes of geranyl chloride demonstrate that the distal olefin forms a stable chelated system (NMR and X-ray structure) see: Akermark B., Hansson S., Krakenberger B., Vitagliano A., Zetterberg K. Organometallics. 3:1984;679
19. Akermark B., Vitagliano A. Organometallics. 4:1985;1275
20. Malkov A.V., Baxendale I.R., Mansfield D.J., Kočovský P. J. Chem. Soc., Perkin Trans. 1. 2001;1234
21. Harwood L.M., Oxford A.J., Thomson C. J. Chem. Soc., Chem. Commun. 1991;1303
22. Godschalx J., Stille J.K. Tetrahedron Lett. 21:1980;2595
23. Trost B.M., Keinan E. Tetrahedron Lett. 21:1980;2595
24. Goliaszewski A., Schwartz J. J. Am. Chem. Soc. 106:1984;5028
25. Goliaszewski A., Schwartz X. Organometallics. 4:1985;417
26. Normal human urothelial (NHU) cell lines were established from surgical specimens taken from patients with no history of urothelial malignancy, as previously described, see: Southgate J., Hutton K.A., Thomas D.F., Trejdosiewicz L.K. Lab. Invest. 71:1974;583
27. 3 cells/well and the cells were grown for 16 h. The growth medium was aspirated, and 200 μL of medium containing the appropriate concentration of 1 was added to 96-well plates in replicates of 6. The cells were exposed to the agent for 24 or 72 h (day 1 and day 3 time points, respectively) at 37°C; the medium was replaced and the cells were cultured for a further 3 days (day 6 time point). Cell growth was assessed using an MTT ([3-(4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) assay on days 0, 1, 3, and 6 after the start of the treatment. 200 μL of 0.5 mg/mL (for NHU) or 0.25 mg/mL (for EJ) MTT (Sigma) was added to the wells of the plate, and plates were incubated at 37°C for 4 h. During this time, the yellow MTT tetrazolium salt was converted to insoluble, purple formazan crystals by mitochondrial dehydrogenase in viable cells. Nonconverted MTT and media were discarded, and the formazan crystals were dissolved in 200 μL DMSO. The absorbance was read at 570 nm relative to a DMSO blank. The data are displayed graphically as a mean value with error bars representing the standard deviation (SD). One way ANOVA was performed using GraphPad InStat to test for significant differences between the treatments and the controls. P values of 0.05 and below were considered to be significant